期刊文献+

HIV-1中和抗体的作用与机制及实验室检测进展 被引量:4

原文传递
导出
摘要 人类免疫缺陷病毒Ⅰ型(HIV-1)中和抗体在防止病毒感染方面起到重要作用。最近的研究表明,中和抗体也能协同细胞免疫应答延缓感染者的疾病进程。HIV-1中和抗体主要通过结合HIV-1感染细胞过程中暴露的各种中间结构而干扰HIV-1进入靶细胞,从而阻断感染的发生。同时,病毒通过变异和外膜糖蛋白(Env)的高度糖基化发生免疫逃逸。目前中和抗体的检测主要依赖于体外中和试验,近年来研究者不断对该试验方案进行优化和标准化。对中和抗体作用的相关机制的逐渐阐明、相关检测技术的发展,必将推进疫苗研究的发展,并为疫苗评价提供新的可信的实验依据。
作者 林怡 钟平
出处 《中国艾滋病性病》 CAS 2008年第6期634-636,共3页 Chinese Journal of Aids & STD
基金 上海市医学重点学科建设项目(05Ⅲ029)
  • 相关文献

参考文献19

  • 1Richman DD, Wrin T, Little SJ, et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection[J].Proc Natl Acad Sci USA,2003,100(7) :4144 - 4149.
  • 2Hirbod T, Kaul R, Reichard C, et al. HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers [ J ] . AIDS, 2008, 22 (6) :727-735.
  • 3Trkola A, Kuster H, Rusert P, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human nantralizing antibodies[J]. Nat Med, 2005,11 (6) :615-622.
  • 4Ruppach H, Nara P, Raudonat I, et al. Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes[J] .J Virol,2000,74(12) :5403-5411.
  • 5Zwick MB, Wang M, Poignard P, et al. Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies [ J ] . J Virol, 2001,75 (24) : 12198-12208.
  • 6Ferrantelli F, Hofmann-Lehmann R, Rasmussen RA, et al. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques [J] .AIDS, 2003,17(3) :301 - 309.
  • 7Cao Y, Qin L, Zhang L, et al. Virologic and immunologic characterization of logn-term survivors of human immunodeficieney virus type 1 infection[J]. N Engl J Med, 1995,332(4) : 201 - 208.
  • 8Humbert M,Antoni S, Brill B, et al, Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma[J] .Eur J Immunol,2007,37(2) :501 - 515.
  • 9Khurana S, Kennedy M, King LR, et al. Identification of a linear peptide recognized by monoclonal antibody 2137 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity[ J ]. J Virol, 2005,79 ( 11 ) :6791 - 6800.
  • 10Beirnaert E, Nyambi P, Willems B, et al. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M(env clade A-H)and group O Primary HIV-1 isolates[ J ]. J Med Virol, 2000,62 ( 1 ) : 14 - 24.

同被引文献77

  • 1刘颖,段丹丽,彭虹,唐海丽,刘沙,张宁,王宁,刘建源,邵一鸣.HIV复制型痘苗病毒载体疫苗免疫原性分析[J].中华实验和临床病毒学杂志,2004,18(3):281-283. 被引量:9
  • 2中国疾病预防控制中心.艾滋病检测技术规范[EB/OL].[2009-09-01].http://www.edcp.org.cn/flfg/fagui/qgazbjcg.doc.
  • 3张光萍,张业勤,翟建新,王业富.HIV的实验室检测技术进展[J].氨基酸和生物资源,2007,29(3):66-69. 被引量:2
  • 4韩志英.HIV实验室检测技术进展[J].中外健康文摘:医药月刊,2007;4(12):127~128.
  • 5李新平,邢辉,邵一鸣.HIV-1耐药性表型检测方法研究进展[J].中国艾滋病性病,2007,13(5):486-488. 被引量:6
  • 6WS293-2008.艾滋病和艾滋病病毒感染诊断标准[S].2008.
  • 7Zhao Y,Yu M, Miller JW,et al. Transfuse and human immuno - de-ficiency virus infections [ J ] . Clin Microbiol, 2002,40 ( 2 ) : 675-678.
  • 8Brian L,Mark WP,Ernest W, et al. Use of an acute sero conversionpanel to evaluate at hirdgeneration enzymelinked immunoassay fordetec-tion of human immunodeficiency virus specific antibodies relative tomultiple ot her assays [ J] . Journal of Clinical Microbiology,2006,44 (5) : 1 856 -1 858.
  • 9Tebourski F, Slim A,Elgaaied A. The significance of combiningWorld Health Organization and center for Disease control criteria to re-solve indeterminate human immunodeficiency virus type - 1 Westernblot results [J] . Diagn Microbiol Infect Dis, 2004, 48 (1): 59-61.
  • 10Sudha T, Lakshmi V, Teja VD. Western blot profile in HIV infection[J] . Indian Dermatol Venereol Leprol, 2006, 72 (5 ): 357 -360.

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部